Study of the immune system of children with neuroblastoma

Deciphering the functional dynamics of the immune system during (immune)therapy in children with neuroblastoma - immunomonitoring in NBL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52494

Enrollment

Registered

2018-07-09

Start date

2023-03-15

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Interventions

None listed

Eligibility

Age

No minimum to 17 Years

Inclusion criteria

Inclusion criteria: Neuroblastoma, between 1 and 18 years at diagnosis Neuroblastoma histological proven diagnosis Informed consent Initial staging of the tumor

Exclusion criteria

Exclusion criteria: Incomplete informed consent Pregnancy

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: immune profiles from NBL patients during (immune)therapy, different percentages (and absolute numbers) and function of immune cells between patients and treatment cycles, functionality in particular NK, T effector and Treg cells, and anti-GD2 plasma levels	—

Secondary

Measure	Time frame
anti-GD2 quantification/measurements	—

Countries

Netherlands

Contacts

Public ContactM.P. Dierselhuis

Prinses Máxima Centrum voor Kinderoncologie

m.p.dierselhuis@prinsesmaximacentrum.nl0889727272

Outcome results